{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:50:39Z","timestamp":1780109439586,"version":"3.54.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","seizure-journal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.seizure.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T20:51:44Z","timestamp":1683319904000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome"],"prefix":"10.1016","volume":"110","author":[{"given":"Rima","family":"Nabbout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-2771","authenticated-orcid":false,"given":"Alexis","family":"Arzimanoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Auvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Berquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Desurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-5896","authenticated-orcid":false,"given":"Douglas","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Nortvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pulitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Helen","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2023.05.003_bib0001","unstructured":"U.S. Food & Drug Administration (FDA). Epidiolex\u00ae (cannabidiol) oral solution: highlights of prescribing information 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/210365s015lbl.pdf (accessed October 18, 2022)."},{"key":"10.1016\/j.seizure.2023.05.003_bib0002","unstructured":"European Medicines Agency. Epidyolex\u00ae 100 mg\/ml oral solution: summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/epidyolex-epar-product-information_en.pdf (accessed May 18, 2022)."},{"key":"10.1016\/j.seizure.2023.05.003_bib0003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2009.10.007","article-title":"Lennox-Gastaut syndrome (LGS): development of conceptual models of health-related quality of life (HRQL) for caregivers and children","volume":"19","author":"Gallop","year":"2010","journal-title":"Seizure"},{"issue":"Suppl. 5","key":"10.1016\/j.seizure.2023.05.003_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.03177.x","article-title":"Definition and natural history of Lennox-Gastaut syndrome","volume":"52","author":"Camfield","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.003_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.003_bib0006","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","article-title":"Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology","volume":"8","author":"Arzimanoglou","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2023.05.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107146","article-title":"Expert opinion: proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients","volume":"110","author":"Montouris","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.05.003_bib0008","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.003_bib0009","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/epi.17274","article-title":"International consensus on diagnosis and management of Dravet syndrome","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.003_bib0010","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.003_bib0011","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/epi.13889","article-title":"Dravet syndrome and its mimics: beyond SCN1A","volume":"58","author":"Steel","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.003_bib0012","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3389\/fneur.2017.00505","article-title":"Expert opinion on the management of Lennox\u2013Gastaut syndrome: treatment algorithms and practical considerations","volume":"8","author":"Cross","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2023.05.003_bib0013","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2023.05.003_bib0014","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2023.05.003_bib0015","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled Phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2023.05.003_bib0016","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2023.05.003_bib0017","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.003_bib0018","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A Phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.seizure.2023.05.003_bib0019","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/epi.16546","article-title":"Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis","volume":"61","author":"Lattanzi","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.003_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/epi4.12569","article-title":"Guidance on Dravet syndrome from infant to adult care: road map for treatment planning in Europe","volume":"7","author":"Cardenal-Mu\u00f1oz","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2023.05.003_bib0021","unstructured":"European Medicines Agency. EMA\/458106\/2019: Epidyolex assessment report 2019. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/epidyolex-epar-public-assessment-report_en.pdf (accessed February 9, 2022)."},{"key":"10.1016\/j.seizure.2023.05.003_bib0022","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: meta-analysis of four randomized controlled trials","volume":"142","author":"Devinsky","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2023.05.003_bib0023","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ane.13351","article-title":"Cannabidiol in conjunction with clobazam: analysis of four randomized-controlled trials","volume":"143","author":"Gunning","year":"2021","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 2","key":"10.1016\/j.seizure.2023.05.003_bib0024","first-page":"135","article-title":"Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam in patients with Lennox-Gastaut syndrome or Dravet syndrome: interim analysis","volume":"63","author":"Nortvedt","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.003_bib0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3389\/fneur.2021.673135","article-title":"Results from an Italian expanded access program on cannabidiol treatment in highly refractory Dravet syndrome and Lennox\u2013Gastaut syndrome","volume":"12","author":"Iannone","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2023.05.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106263","article-title":"Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam","volume":"160","author":"Savage","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2023.05.003_bib0027","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2023.05.003_bib0028","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.yebeh.2019.07.008","article-title":"Drug\u2013drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program","volume":"98","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.05.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108239","article-title":"The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome","volume":"123","author":"Auvin","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.05.003_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.seizure.2021.05.014","article-title":"Two-center experience of cannabidiol use in adults with Dravet syndrome","volume":"91","author":"Silvennoinen","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2023.05.003_bib0031","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fneur.2020.00829","article-title":"Slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study","volume":"11","author":"D'Onofrio","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2023.05.003_bib0032","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2023.05.003_bib0033","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40263-020-00726-4","article-title":"A Phase II randomized trial to explore the potential for pharmacokinetic drug-drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy","volume":"34","author":"Ben-Menachem","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2023.05.003_bib0034","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies \u2013 utility and caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J R Coll Physicians Edinb"},{"key":"10.1016\/j.seizure.2023.05.003_bib0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yebeh.2014.12.028","article-title":"The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome","volume":"44","author":"Aras","year":"2015","journal-title":"Epilepsy Behav"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123001255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123001255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T16:42:06Z","timestamp":1722616926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131123001255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":35,"alternative-id":["S1059131123001255"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2023.05.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}